Edwards Lifesciences Buy Hold or Sell Recommendation

EW -- USA Stock  

USD 153.68  2.21  1.46%

Allowing for the 30-days total investment horizon, and your above average risk tolerance our recommendation regarding Edwards Lifesciences Corporation is 'Strong Buy'. Macroaxis provides Edwards Lifesciences buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding EW positions. The advice algorithm takes into account all of Edwards Lifesciences available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from EW buy-and-hold prospective. Additionally see Edwards Lifesciences Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for muliple equity instruments please use Instant Ratings tool.

Time Horizon

Risk Tolerance

Execute Advice
Sell Edwards LifesciencesBuy Edwards Lifesciences
Strong Buy


Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

Piotroski F Score

Financial Leverage

For the selected time horizon Edwards Lifesciences Corporation has a risk adjusted performance of 0.1698, jensen alpha of 0.2015, total risk alpha of 0.014273, sortino ratio of 0.1689 and treynor ratio of 0.3725
Macroaxis provides buy, hold, or sell suggestion on Edwards Lifesciences to complement and cross-verify current analyst consensus on Edwards Lifesciences Corporation. Our buy, hold, or sell recommendation engine determines the organization potential to grow exclusively from the prospective of investors current risk tolerance and investing horizon. To make sure Edwards Lifesciences is not overpriced, please confirm all Edwards Lifesciences fundamentals including its EBITDA, Earnings Per Share, Z Score, as well as the relationship between Debt to Equity and Total Asset . Given that Edwards Lifesciences has Price to Earning of 50.47 times, we urge you verify Edwards Lifesciences Corporation market performance and probability of bankruptcy to make sure the company can sustain itself in the current economic cycle given your prevailing risk tolerance and investing horizon.

Edwards Lifesciences Thematic Classifications

Obamacare Repeal IdeaObamacare Repeal
Large healthcare related equities associated with Obamacare
Macroaxis Picks IdeaMacroaxis Picks
Macroaxis daily picks
Medical Equipment IdeaMedical Equipment
USA Equities from Medical Equipment industry as classified by Fama & French

Edwards Lifesciences Returns Distribution Density

Mean Return0.37Value At Risk1.28
Potential Upside1.85Standard Deviation1.03
 Return Density 

Institutional Investors

Security TypeSharesValue
Vanguard Group IncCommon Shares21.5 M3.1 B
Blackrock IncCommon Shares15.5 M2.3 B
State Street CorpCommon Shares8.2 M1.2 B
Bank Of New York Mellon CorpCommon Shares7.5 M1.1 B
Sands Capital Management LlcCommon Shares6.9 M1 B
Fmr LlcCommon Shares6.7 M977.5 M
Wellington Management Group LlpCommon Shares6.3 M923.1 M

Edwards Lifesciences Greeks

Alpha over DOW
Beta against DOW=0.98
Overall volatility
Information ratio =0.19

Edwards Lifesciences Volatility Alert

Edwards Lifesciences Corporation has relatively low volatility with skewness of -0.34 and kurtosis of -0.38. However, we advise all investors to independently investigate Edwards Lifesciences Corporation to ensure market all accessible information is consistent with the expectations about its upside potential and future risk-adjusted return.
 Better Than Average     
 Worse Than Average Compare Edwards Lifesciences to competition

Edwards Lifesciences Fundamental Vs Peers

FundamentalsEdwards LifesciencesPeer Average
Return On Equity21.51 % (15.17) %
Return On Asset11.47 % (15.64) %
Profit Margin18.50 % (5.50) %
Operating Margin30.24 % (10.91) %
Current Valuation30.78 B152.14 B
Shares Outstanding209.39 M1.43 B
Shares Owned by Insiders3.94 % 6.91 %
Number of Shares Shorted2.38 M3.24 M
Price to Earning50.47 times40.69 times
Price to Book10.16 times14.44 times
Price to Sales9.07 times17.81 times
Revenue3.55 B9.85 B
Gross Profit2.56 B21.75 B
EBITDA1.07 B1.41 B
Net Income656.6 M517.71 M
Cash and Equivalents1.4 B3.89 B
Cash per Share6.69 times5.17 times
Total Debt1.19 B7.36 B
Debt to Equity37.70 % 0.72 %
Current Ratio2.28 times3.30 times
Book Value Per Share15.12 times13.64 times
Cash Flow from Operations440.98 M1.25 B
Short Ratio2.27 times2.09 times
Earnings Per Share3.05 times2.30 times
Price to Earnings To Growth2.28 times1.22 times
Number of Employees12.2 K10.67 K
Market Capitalization32.18 B29.78 B
Total Asset4.06 B126.86 B
Retained Earnings3.91 B38.24 B
Working Capital1.57 B3.58 B
Current Asset2.05 B36.8 B
Current Liabilities476.2 M33.34 B
   Acquisition by Michael Mussallem of 27625 shares of Edwards Lifesciences subject to Rule 16b-3 [view details]

Edwards Lifesciences Alerts

Trading Alerts and Improvement Suggestions

Latest Analysts View

Edwards Lifesciences Current Analysts Recommendations

Target Median Price160.00
Target Mean Price156.00
Recommendation Mean2.00
Target High Price177.00
Number Of Analyst Opinions19
Target Low Price118.00
Additionally see Edwards Lifesciences Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for muliple equity instruments please use Instant Ratings tool. Please also try Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Search macroaxis.com